Cathepsin S and an asparagine‐specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro

The biochemical characterization of antigen degradation is an important basis for a better understanding of both the immune response and autoimmune diseases mediated by MHC class II molecules.In this study we used high‐performance liquid chromatography and mass spectrometry to analyze the processing of myelin basic protein (MBP), a potential autoantigen implicated in the pathogenesis ofmultiple sclerosis. We resolved the kinetics of MBP processing by lysosomal extracts or purified endocytic proteases, identified the major cleavage sites during this process and assigned them to the activity of proteolytic enzymes. Proteolytic processing of MBP is mostly guided along the hydrophobic regions of the protein. It is initiated by two proteolytic steps (after N92 and S110) that are performed by an asparagine‐specific endopeptidase (AEP) and by cathepsin (Cat) S, respectively. The resulting processing intermediates are converted into more than 60 different species of 20–40‐mers due to the activity of endopeptidases including CatS, D and L. The fragments thus generated are subsequently degraded by C‐ or N‐terminal trimming. Strikingly, the initial cleavages during MBP processing affect two immunodominant regions of the potential autoantigen [MBP(85–99) and MBP(111‐129)] in an inverse manner. CatS directly generates the N terminus of the epitope MBP(111–129)in large quantities during the initial phase of processing, which might explain the immunogenicity of this region in spite of its relatively poor binding to HLA‐DR4. In contrast, the dominant cleavage by AEP mediates the destruction of MBP(85–99) unless the epitope is protected, e.g. by binding to HLA‐DR. Our results thus characterize the proteolytic events during processing of MBP on a molecular level and suggest a biochemical basis for the immunogenicity of the immunodominant epitopes, which could serve as a guideline for future therapeutic strategies.

[1]  R Crowther,et al.  Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure-activity relationships, and X-ray crystal structures. , 2000, Journal of medicinal chemistry.

[2]  H. Chapman,et al.  Endosomal proteolysis and MHC class II function. , 1998, Current opinion in immunology.

[3]  C Oseroff,et al.  Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones , 1994, The Journal of experimental medicine.

[4]  A. Rudensky,et al.  The role of lysosomal proteinases in MHC class Il‐mediated antigen processing and presentation , 1999, Immunological reviews.

[5]  P. Bohley.  Surface hydrophobicity and intracellular degradation of proteins. , 1996, Biological chemistry.

[6]  Eric O Long,et al.  A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis , 1991, The Journal of experimental medicine.

[7]  J. Seyer,et al.  The sequential limited degradation of bovine myelin basic protein by bovine brain cathepsin D. , 1979, The Journal of biological chemistry.

[8]  J. Palmer,et al.  Vinyl sulfones as mechanism-based cysteine protease inhibitors. , 1995, Journal of medicinal chemistry.

[9]  Eric O Long,et al.  Antigen presentation mediated by recycling of surface HLA-DR molecules , 1995, Nature.

[10]  H. Kirschke,et al.  Cathepsin S from bovine spleen. Purification, distribution, intracellular localization and action on proteins. , 1989, The Biochemical journal.

[11]  D. Mathis,et al.  Determinant capture as a possible mechanism of protection afforded by major histocompatibility complex class II molecules in autoimmune disease , 1993, The Journal of experimental medicine.

[12]  H. Kirschke,et al.  The specificity of bovine spleen cathepsin S. A comparison with rat liver cathepsins L and B. , 1989, The Biochemical journal.

[13]  V. Turk,et al.  Kinetics of the pH-induced inactivation of human cathepsin L. , 1993, Biochemistry.

[14]  Hidde L. Ploegh,et al.  Cathepsin S Controls the Trafficking and Maturation of Mhc Class II Molecules in Dendritic Cells , 1999, The Journal of cell biology.

[15]  N. Rawlings,et al.  Cloning, Isolation, and Characterization of Mammalian Legumain, an Asparaginyl Endopeptidase* , 1997, The Journal of Biological Chemistry.

[16]  Eric O Long,et al.  HLA‐DR‐restricted presentation of purified myelin basic protein is independent of intracellular processing , 1997, European journal of immunology.

[17]  H. Bahn,et al.  Monoclonal antibodies against cathepsin L and procathepsin L of different species. , 1997, Hybridoma.

[18]  C. Watts,et al.  Control of antigen presentation by a single protease cleavage site. , 2000, Immunity.

[19]  A. Boots,et al.  Antigen processing by endosomal proteases determines which sites of sperm‐whale myoglobin are eventually recognized by T cells , 1991, European journal of immunology.

[20]  C. Watts,et al.  Capture and processing of exogenous antigens for presentation on MHC molecules. , 1997, Annual review of immunology.

[21]  M. Bogyo,et al.  Antigen presentation: A protease draws first blood , 1998, Nature.

[22]  H. Chapman,et al.  Emerging roles for cysteine proteases in human biology. , 1997, Annual review of physiology.

[23]  Alan J. Barrett,et al.  An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation , 1998, Nature.

[24]  G. Dranoff,et al.  Cathepsin S required for normal MHC class II peptide loading and germinal center development. , 1999, Immunity.

[25]  H. Kalbacher,et al.  A rapid method to separate endosomes from lysosomal contents using differential centrifugation and hypotonic lysis of lysosomes. , 1999, Journal of immunological methods.

[26]  J. V. van Noort,et al.  Cathepsin D, but not cathepsin B, releases T cell stimulatory fragments from lysozyme that are functional in the context of multiple murine class II MHC molecules , 1994, European journal of immunology.

[27]  Eric O Long,et al.  Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. , 1990, Journal of immunology.

[28]  H. Ploegh,et al.  Role for Cathepsin F in Invariant Chain Processing and Major Histocompatibility Complex Class II Peptide Loading by Macrophages , 2000, The Journal of experimental medicine.

[29]  J. Deussing,et al.  Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[30]  H. Weiner,et al.  T-cell recognition of an immuno-dominant myelin basic protein epitope in multiple sclerosis , 1990, Nature.

[31]  A. Rudensky,et al.  Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. , 1998, Science.

[32]  H. Ploegh,et al.  Proteolysis in MHC class II antigen presentation: who's in charge? , 2000, Immunity.

[33]  S. Buus,et al.  MHC molecules protect T cell epitopes against proteolytic destruction. , 1992, Journal of immunology.

[34]  A. Lanzavecchia,et al.  Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants , 1995, The Journal of experimental medicine.

[35]  D E Banks,et al.  Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residues 111-129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire. , 1997, The Journal of clinical investigation.